Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Breezula Phase III 12-Month Data Released by Cosmo Pharma

       42 upvotes 5 months ago
      Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

      community GT20029 - Promising phase II results

       16 upvotes 2 years ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

    Learn

    3 / 801 results